Bazedoxifene, a therapeutic approved by the U.S. Food and Drug
Administration for the prevention of osteoporosis, suppressed the
growth of pancreatic tumors by inhibiting the IL-6/STAT3 signaling
pathway that the cancer cells use to survive and multiply, according to
preclinical data.
IL-6 is a cytokine, a type of small protein, which plays an important
role in cancer development, and high serum IL-6 levels are a poor
prognostic factor for overall survival in pancreatic cancer; therefore,
IL-6 is considered a viable target for pancreatic cancer therapy.
Bazedoxifene is a third-generation selective estrogen receptor
modulator, which received FDA approval in 2013 as part of a combination
drug for the prevention of postmenopausal osteoporosis in women.
The researchers noted that some of the limitations of the study include
that bazedoxifene may need to be modified chemically to be more
efficacious as single agent, and/or it may need to be combined with
other drugs such as nab-paclitaxel.
No comments:
Post a Comment